Beyondspring (BYSI) Upgraded to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Beyondspring (NASDAQ:BYSI) from a sell rating to a hold rating in a report published on Tuesday morning.

According to Zacks, “BeyondSpring Inc. is a clinical stage biopharmaceutical company. It focused on the development of cancer therapies. The Company’s lead product consists of into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia. BeyondSpring Inc. is based in New York, United States. “

Several other analysts also recently weighed in on the stock. Maxim Group set a $52.00 target price on shares of Beyondspring and gave the company a buy rating in a report on Thursday, December 14th. HC Wainwright set a $60.00 target price on shares of Beyondspring and gave the company a buy rating in a report on Friday, December 15th. Finally, Seaport Global Securities initiated coverage on shares of Beyondspring in a report on Tuesday, December 5th. They issued a buy rating and a $56.00 target price for the company. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Beyondspring presently has an average rating of Buy and a consensus price target of $54.50.

Shares of Beyondspring (NASDAQ:BYSI) opened at $25.74 on Tuesday. Beyondspring has a 1-year low of $16.55 and a 1-year high of $48.49.

Beyondspring (NASDAQ:BYSI) last posted its earnings results on Thursday, November 9th. The company reported ($0.68) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.69) by $0.01. equities analysts anticipate that Beyondspring will post -4.41 earnings per share for the current year.

A hedge fund recently bought a new stake in Beyondspring stock. Tanaka Capital Management Inc. bought a new stake in Beyondspring Inc (NASDAQ:BYSI) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 21,322 shares of the company’s stock, valued at approximately $914,000. Beyondspring comprises about 2.1% of Tanaka Capital Management Inc.’s investment portfolio, making the stock its 16th largest position. Tanaka Capital Management Inc. owned about 0.10% of Beyondspring at the end of the most recent quarter. 1.22% of the stock is owned by institutional investors.

WARNING: This article was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at

About Beyondspring

BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).

Get a free copy of the Zacks research report on Beyondspring (BYSI)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with's FREE daily email newsletter.

Leave a Reply